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Previous research has shown that mifepristone can prevent and reverse weight gain in animals and human subjects taking
antipsychotic medications. This proof-of-concept study tested whether a more potent and selective glucocorticoid receptor
antagonist could block dietary-induced weight gain and increase insulin sensitivity in mice. Ten-week-old, male, C57BL/6J mice
were fed a diet containing 60% fat calories and water supplemented with 11% sucrose for 4 weeks. Groups (n = 8) received
one of the following: CORT 108297 (80mg/kg QD), CORT 108297 (40mg/kg BID), mifepristone (30mg/kg BID), rosiglitazone
(10mg/kg QD), or vehicle. Compared to mice receiving a high-fat, high-sugar diet plus vehicle, mice receiving a high-fat, high-
sugar diet plus either mifepristoneor CORT 108297 gained signiﬁcantlyless weight. At the end of the four week treatment period,
mice receiving CORT 108297 40mg/kg BID or CORT 108297 80mg/kg QD also had signiﬁcantly lower steady plasma glucose
than mice receiving vehicle. However, steady state plasma glucose after treatment was not highly correlated with reduced weight
gain, suggestingthatthe eﬀect ofthe glucocorticoid receptor antagonistoninsulinsensitivity maybe independent ofits mitigating
eﬀect on weight gain.
1.Introduction
The role of insulin resistance in dietary-induced obesity is
of increasing concern, as the prevalence of both obesity and
type 2 diabetes approaches 1 in 3 in the United States
population [1]. Mortality, morbidity, and health care costs
mandate increased scientiﬁc eﬀort towards discovery of
underlying mechanisms of these illnesses in a quest to
develop maximally eﬀective therapies.
The co-occurrence of excessive glucocorticoid activity
and metabolic problems has long been noted [2]. In 2000,
Chrousos formally hypothesized that stress-related hyper-
cortisolism and glucocorticoid hypersensitivity are involved
in the pathogenesis of the metabolic syndrome and obesity
[3]. The potential intermediary role of cortisol in the
connection between insulin sensitivity and weight gain can
be readily observed from the extreme case of Cushing’s
syndrome. The deﬁning characteristic of this syndrome is
chronicelevationofcirculatingglucocorticoids;thehallmark
symptoms of Cushing’s syndrome are progressive truncal
obesity and insulin resistance due to chronically elevated
glucocorticoid levels [4]. Endogenous Cushing’s syndrome
is caused by corticotropin (ACTH)-producing pituitary
tumors (Cushing’s disease), by ectopic ACTH secretion
from a nonpituitary tumor, and by cortisol secretion by an
adrenal adenoma or carcinoma. The insulin resistance seen
in Cushing’s syndrome causes its major symptoms (obesity,
glucose intolerance, hypertension, and dyslipidemia); it is
thought that a similar mechanism is responsible for the
metabolic syndrome [4, 5], although patients who have the
metabolic syndrome by deﬁnition do not have ACTH or
cortisol producing tumors. Pharmacological reduction of
glucocorticoid activity can be achieved via several mech-
anisms of action, including neuromodulatory compounds2 Journal of Nutrition and Metabolism
which reduce corticotropin (ACTH) release from pituitary
tumors, steroidogenesis inhibitors which reduce cortisol lev-
elsbyadrenolyticactivity and/ordirectenzymaticinhibition,
and ﬁnally glucocorticoid receptor (GR) antagonists which
block cortisol action at its receptor [6, 7].
Manipulation of cortisol levels has been shown to alter
insulinsensitivity[2,8].Invivoexperimentshaveshownthat
glucocorticoids impair insulin-dependent glucose uptake in
the periphery and enhance gluconeogenesis in the liver
[9, 10]. Nieman et al. [11] reported the ﬁrst case study
demonstrating that mifepristone, a glucocorticoid antago-
nist, eﬀectively corrected body weight gain and carbohy-
drate metabolism changes in Cushing’s syndrome. Other
investigational studies of Cushing’s syndrome have shown
that mifepristone exerts strong antiglucocorticoid eﬀects
and leads to rapid clinical improvement with acceptable
side eﬀects [12–16]. More recently, mifepristone has been
reported to successfully ameliorate obesity and metabolic
perturbations caused by antipsychotic medications in
healthy humans [17, 18].
The purpose of this proof-of-concept study was to deter-
mine whether a newly identiﬁed, selective glucocorticoid
receptor antagonist, CORT 108297, could block dietary-
induced weight gain and increase insulin sensitivity in mice.
Unlike mifepristone, CORT 108297 has no activity at the
progesterone receptor. CORT 108297 was previously shown
to attenuate weight gain induced by the antipsychotic medi-
cation olanzapine [19].
2.Materialsand Methods
2.1. Animals and Diets. Forty (N = 40) ten-week-old, male,
C57BL/6J mice were fed ad libitum a diet containing 60%
fat calories (D12492, Research Diets Inc.) and water sup-
plemented with 11% sucrose (decarbonated Sprite) for 4
weeks. In addition, they received one of the following ﬁve
treatments: CORT 108297 (80mg/kg QD), CORT 108297
(40mg/kg BID),mifepristone (30mg/kgBID), rosiglitazone,
an oral glycemic medication (10mg/kg QD), or vehicle
(10% DMSO in 0.5% CMC). CORT 108297 is a selective
glucocorticoid receptor antagonist and has a GR binding
and functional proﬁle similar to mifepristone with sub-
nanomolar aﬃnity for human GR and less than 10nM GR
functional activity in a luciferase-based reporter gene assay.
Unlike mifepristone, it has no activity at the progesterone
(PR) receptor [20]. An additional control group (n = 8) was
fed a standard chow diet and tap water and did not receive
any treatment.
2.2.OutcomeMeasures. The primary outcomes,body weight
and insulin sensitivity, were measured weekly. Insulin sensi-
tivity was measured by deriving steady state glucose values
from the insulin suppression test (IST). Mice were fasted
for 4 hours (from 8 AM to noon) prior to the IST. A
combination of 300µL of saline with insulin (1U/kg), glu-
cose (1.3g/kg), and somatostatin (0.13mg/kg) was injected
intraperitoneally. Blood glucose values were obtained from
tail vein blood using a commercially available glucometer.
Measurements were taken at 0, 60, 70, and 80 minutes post-
injection. All procedures conformed to the Guides for Care
and Use of Laboratory Animals of the National Institutes of
Healthand were approvedbytheAnimal Subjectscommittee
of Stanford University.
2.3. Statistical Analysis. For comparing change in weight
across treatment groups, a multivariate analysis of variance
model (MANOVA) was used with treatment group as a
ﬁxed factor. The primary analyses of interest deﬁned ap r i o r i
were the contrasts between the vehicle group (high-fat/high-
sugar diet with no treatment) versus each active treatment
group (i.e., CORT 108297 40 BID, CORT 108297 80 QD,
mifepristone, and rosiglitazone). Analyses of steady state
plasma glucose were conducted using nonparametric Mann-
Whitney tests normalized to the z distribution. Associations
between weight and steady state plasma glucose levels were
tested using Pearson r.
3.Results
3.1. Body Weight. There were statistically signiﬁcant group
diﬀerences in body weight gain (MANOVA F = 8.8, df =
5,48; P<. 0001). The high-fat and high-sucrose diet induced
signiﬁcant weight gain: mice receiving the high-fat and high-
sucrose dietbutnottreatment (i.e.,thevehiclegroup)gained
an average of 6 grams across the 4-week study (m = 6.3, sd =
1.7), whereas mice fed standard chow gained an average of 2
grams (M = 2.1, SD = .9; P<. 0001). Mice receiving either
mifepristone or CORT 108297 in conjunctionwith the high-
fat/ high-sucrose diet exhibited signiﬁcantly less weight gain
than mice receiving vehicle (mifepristone 30mg/kg BID
versus vehicle: P<. 01; CORT 108297—80mg/kg QD versus
vehicle: P<. 0001; CORT 108297—40mg/kg BID versus ve-
hicle: P<. 0001).
3.2. Steady State Plasma Glucose. After 4 weeks, there were
statistically signiﬁcant diﬀerences between treatment groups
in steady state plasma glucose. Compared to the group
receiving a high-fat diet plus vehicle (M = 221, SD = 40),
mice receiving CORT 108297 80mg/kg QD (M = 196,
SD = 28; Mann-Whitney P<. 05) and mice receiving CORT
108297 40mg/kg BID (M = 185, SD = 41; Mann-Whitney
P<. 05) had signiﬁcantly lower steady state plasma glucose.
Steadystateplasma glucosewas alsosigniﬁcantly lower inthe
mice treated with mifepristone (M = 193, SD = 32; Mann-
Whitney P<. 05) or rosiglitazone (M = 161, SD = 38;
Mann-Whitney P<. 05). Mean SSPG and standard errors
for each group are shown in Figure 2.
3.2.1. Association between Body Weight and Steady State
Plasma Glucose. Given that statistically signiﬁcant mitiga-
tion of weight gain and steady state plasma glucose were
both observed, a signiﬁcant linear correlation was expected
between weight change and plasma glucose levels. However,
correlation analyses indicated no signiﬁcant association
between body weight gain and steady state plasma glucose
(r = +.10, P = .98). Animals that exhibited less weight gainJournal of Nutrition and Metabolism 3
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Figure 1: Mean body weight by treatment group. The mean body
weights (grams) for the six groups of mice across the four week
study. Vertical bars represent standard errors.
were no more likely tohave lower plasma glucosevaluesthan
animals that exhibited greater weight gain.
4.Discussion
Signiﬁcant body weight gain in mice was induced in a short
period of time using a high-fat and high-sucrose diet. Mice
receiving treatment with CORT 108297 in conjunction with
this diet had signiﬁcantly less body weight gain than vehicle-
treated mice, suggesting that this selective glucocorticoid
antagonist is potentially capable of mitigating dietary-
induced weight gain. Insulin resistance was also increased
due to the high-fat and high-sucrose diet. Mice receiving
CORT 108297 had signiﬁcantly less elevation in steady state
glucose values than mice that received vehicle.
In the current study, the eﬀects of CORT 108297 on
weight gain were comparable with the observed eﬀects
of mifepristone. The observed attenuation of weight gain
is consistent with ﬁndings from previous animal studies
and human clinical trials on mifepristone [17, 18, 21].
Two separate animal studies revealed that mifepristone
[21] and CORT 108297 [19] attenuated medication-induced
weight gain caused by ingestion of olanzapine, a medication
consistently associated with obesity and metabolic prob-
lems. In humans, two randomized clinical trials showed
that mifepristone signiﬁcantly inhibited the body weight
gain and metabolic disturbances caused by olanzapine and
risperidone [17, 18]. Both mifepristone and CORT 108297
block activity at the glucocorticoid receptor, whereas CORT
108297, unlike mifepristone, does not block progesterone
receptor activity. This implicates the blockade of glucocor-
ticoid pathway—rather than the progesterone pathway—as
the potential mechanism explaining mifepristone’s previ-
ously observed eﬀects on weight gain.
Whereas the prior literature demonstrated the role of
glucocorticoid receptor antagonists for mitigating weight
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Figure 2: Steady state plasma glucose after 4 weeks. Height of bar
represents the mean steady state plasma glucose value at the end of
the four-week study. Thin bars indicate standard error.
gain induced by antipsychotic medication usage, the current
animal study implies that CORT 108297 can potentially
suppress the weight gain induced by diet and, further,
that it may increase insulin sensitivity. The concomitant
eﬀects of CORT 108297 on weight gain and steady state
plasma glucose after four weeks of treatment in the current
study must be viewed in the context of the nonsignif-
icant correlation between the two variables. This result
raises the possibility that the eﬀects of CORT 108297 on
the two outcomes are “independent” eﬀects; that is, the
attenuation of insulin sensitivity may not be merely a
consequence of the compound’s mitigating eﬀect on weight
gain.
Interestingly, mice receiving 40mg/kg of CORT 108297
administered twice per day (i.e., total daily dose of80mg/kg)
had less weight gain and lower plasma glucose compared
withmicereceiving80mg/kgoncedaily(seeFigures1and2).
While not statistically signiﬁcant, the directionality of this
observation may reﬂect the relatively short half-life of CORT
108297 in rodents.
Inferences from this study are limited due to the proof-
of-concept design which was not statistically powered to
evaluate a large number of outcome variables. For example,
this study did not collect data on food intake. Nonetheless,
the eﬀect sizes observed on the two outcomes that were
measured, weight and insulin resistance, indicate that this
line of research should be continued. Although larger
suﬃciently powered studies are needed, the lack of statistical
association between weight gain and plasma glucose suggests
that the eﬀects of CORT 108297 on insulin sensitivity may
occurindependentlyoftheGRantagonist’seﬀectsonweight.
More comprehensive studies, which evaluatefood intakeand
other metabolic measures, are warranted and could provide
information about the underlying mechanisms involved in
the relationship between glucocorticoids, weight gain, and
insulin resistance.4 Journal of Nutrition and Metabolism
Ifthecurrentﬁndingsarereplicatedandextended,CORT
108297 would oﬀer an advantage over mifepristone given its
lack of activity at the progesterone receptor. CORT108297 is
currently in Phase 2 testing.
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